Jolanta Opara

C++ Developer at PrecisionLife

Jolanta Opara has a diverse work experience in the field of C++ development and software engineering. Jolanta is currently working as a C++ Developer at PrecisionLife since April 2021. Prior to this, they served as a Polish expert at the ISO C++ Committee starting from July 2019.

From August 2020 to March 2021, Jolanta worked as a Programista C++ at LizardFS. Before that, they were a Senior Software Engineer at Mobica from January 2019 to June 2020. In this role, they represented the company in the Technical Committee 331 for Programming Languages and led a project for a major maritime devices provider, focusing on developing new features for navigation equipment.

Jolanta's earlier experience includes working as a Software Engineer at Mobica from December 2015 to January 2019. Jolanta was also a Junior Software Engineer at Samsung Electronics Poland R&D Center from March 2013 to November 2015. In this role, they contributed to the development of the Software Upgrade feature on a new platform for digital TV and led two projects with 11 developers.

Jolanta started their career with a student internship at Instytut Biocybernetyki i Inżynierii Biomedycznej Polskiej Akademii Nauk in July 2011.

Overall, Jolanta Opara has a strong background in C++ development, software engineering, and project leadership.

Jolanta Opara pursued their education at the Warsaw University of Technology from 2008 to 2014. During this time, they obtained a Master of Engineering degree in Biomedical Engineering from the Faculty of Electronics and Information Technology.

Location

Warszawa, Poland

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


PrecisionLife

Our unique approach powers an Innovation Engine creating new treatment opportunities for precision biopharma and healthcare.We generate the deepest understanding of the biology driving chronic diseases, stratifying patient populations at an unprecedented resolution to define new subgroups of patients.With these insights we discover novel drugtargets, drug repositioning candidates, and biomarkers to identify the patients who will benefit from them.#techbio #precisionmedicine


Employees

11-50

Links